Here is why ACRX will be one of 2014 top biotech performers:
I listened to the CC three times. Seems like they are talking to partners in multiple countries, not only Europe, and are selecting the "RIGHT partner", not a partner. During the last CC the mentioned they were looking for a foreign partner, so to hear that partner(s) are interested in multiply countries sounds awesome. Also, I was very surprised that even for drug candidates 02 & 03, listen to the CC....they are fielding MULTIPLE partner discussions not just a partner discussion. Buying ACRX hand over fist & waiting. Not playing the swings. ACRX has the potential, phase 3 tested solution to Morphine, a $3 billion dollar market. Looking for the NDA to be accepted this month with an FDA in Q3 2014. STRONG BUY.